# EDGAR Filing Document

**Accession Number:** 0001783036
**File Stem:** 0000000000-25-006427
**Filing Date:** 2025-6
**Character Count:** 5009
**Document Hash:** 14219a9b84cb4ef5234abe6ee7a2ddab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-006427.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0000000000-25-006427

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250618

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewcelX Ltd.
- **CENTRAL INDEX KEY:** 0001783036
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-284075

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **BUSINESS PHONE:** 41-41-618-80-00

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NLS Pharmaceutics Ltd.
- **DATE OF NAME CHANGE:** 20190719
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-24-113211

## Text-Extract

```

                                                             June 18, 2025

Alexander Zwyer
Chief Executive Officer
NLS Pharmaceutics Ltd.
The Circle 6
8058 Zurich, Switzerland

       Re: NLS Pharmaceutics Ltd.
           Amendment No. 3 to Registration Statement on Form F-4
           Filed June 9, 2025
           File No. 333-284075
Dear Alexander Zwyer:

     We have reviewed your amended registration statement and have the
following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our April 15,
2025 letter.

Amendment No. 3 to Registration Statement on Form F-4
Kadimastem Business
Kadimastem Overview, page 199

1.     We note your reference to NCT0348205010. To the extent this is intended
to be a
       reference to NCT03482050, please revise your disclosure accordingly.
Alternatively,
       please advise.

       We further note your statements that transplantation of AstroRx cells
enhances
       treatment and slows disease progression. Please revise to clarify, if
true, that there was
       no placebo component in the trial in which AstroRx was evaluated, that
the trial was
       not designed to evaluate efficacy and that is it is possible that
effects observed in this
       trial will not be demonstrated in larger clinical trials in the future.
 June 18, 2025
Page 2

Encap-IsletRx, page 211

2.     We note your response to prior comment 3 and reissue. Given that you
have yet to
       conduct studies demonstrating the efficacy of this product candidate and
delivery
       strategy, please remove references to "efficacy" in the title of your
figure on page
       212 labeled "Encap-IsletRx Preclinical Efficacy."
Key Commercial Agreements, page 212

3.     We note Kadimastem entered into a collaboration agreement with Pluir,
Inc. for
       clinical manufacturing of Kadimastem's product. Please expand the
discussion to
       describe all material terms of the agreement, including a description of
each party's
       rights and obligations and a summary of the term and termination
provisions.
Unaudited Pro Forma Condensed Combined Financial Statements
Note 2 - Pro Forma Adjustments, page 268

4.     Refer to adjustment (O). We note that you have a pro forma adjustment
for
       approximately $15.5 million for    Intangible assets     primarily
implied R&D.    Please
       explain what you mean by implied R&D and explain how the value was
       determined. Cite any authoritative literature upon which you relied.
5.     As a related matter, we note on the face of your pro forma balance sheet
this
       adjustment has been referred to as goodwill rather than Intangible
assets     primarily
       implied R&D. Please advise us or revise your filing accordingly.
       Please contact Eric Atallah at 202-551-3663 or Angela Connell at
202-551-3426 if
you have questions regarding comments on the financial statements and related
matters. Please contact Doris Stacey Gama at 202-551-3188 or Alan Campbell at
202-551-
4224 with any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Ron Ben-Bassat, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._